A Study Investigating a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Participants Aged 6 to 64 Years With Illnesses That Mean They Are More Likely to Get Pneumococcal Disease
Final Report: A Phase 3, Multicenter, Single-Arm, Open-Label Study to Assess the Safety, Tolerability, and Immunogenicity of a Single Dose of 13-Valent Pneumococcal Conjugate Vaccine in Japanese Subjects Aged 6 to 64 Years Who are Considered to be at Increased Risk of Pneumococcal Disease and Who are Naive to Pneumococcal Vaccines
Category & Conditions: Vaccine-related Conditions
Medicine: PREVNAR 13(PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE [DIPHTHERIA CRM197 PROTEIN])
ClinicalTrials.gov Identifier (NCT): NCT03571607
Protocol ID: B1851172
PrintDownloadOpen Plain Language Summary Result: Click here